Compare Expeditors International of Wshngtn Inc (EXPD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Novartis AG — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 11× Expeditors International of Wshngtn Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Novartis AG for 82 Days on average.
| EXPD | NVS | |
|---|---|---|
Market Cap | $24.81B | $274.00B |
Volume | 832,787 | 1,852,137 |
Sector | Industrials | Health |
52-Week High | $194.12 | $168.62 |
52-Week Low | $113.13 | $121.80 |
Typical Hold Time | 43 Days | 82 Days |
Enterprise Value | $24.34B | $315.32B |
Dividend Yield | 0.85% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.0% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 42.6% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts. Institutional activity shows mixed positioning with some major funds increasing stakes while others reduced exposure.
While EXPD shows strong operational metrics and earnings momentum, the stock trades above analyst consensus target of $174.86, suggesting limited near-term upside. Risks include competitive pressures and potential freight market volatility. The company's focus on efficiency and shareholder returns provides stability, but valuation remains elevated at 27.78 P/E ratio.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
